OBJECTIVES: To assess the burden of disease in peripheral Spondyloarthritis (SpA) – Psoriatic Arthritis (PsA), and axial SpA – non-radiographic axial SpA (nr-axSpA) and Ankylosing Spondylitis (AS), in Mexico. METHODS: Data were gathered from the Adelphi Real World 2015 DSPRESULTS: Health Services: PRF data showed that the mean number of specialist consults in the last year was 8.1 per patient, and 4% (n=9) had a hospital admission to treat SpA-related complications. Further, 4.9% (n=11) reported having received an injection/infusion while in hospital; while 29.8% (n=67) of patients reported an injection/infusion in an outpatient setting. Patient Out-of-pocket Costs: PSC data (n=19) revealed that patients reported treatment costs for the last 3 months of $5.26 (MXN), equivalent to 0.42% of their quarterly household income. Societal: PSC data (n=209) showed that 56.5% of patients were employed. Additionally, 93 patients reported a mean of 2.2 unscheduled days off in the last 3 months due to SpA. WPAI (n=106) outcomes revealed a 52.6% overall work impairment, and 209 patients reported a 54.4% activity impairment due to SpA. Humanistic: Respondents (n=221) had an EQ-5D mean of 0.66, and the SF-36 (n=176) physical and mental component summary scores were 39.9 and 38.5 respectively. SF-36 bodily pain, social functioning, and emotional domain mean scores were 52.5, 56.1, and 54.6 respectively. Additionally, 72% reported SpA has been or currently is a major problem in their life, and 84% (n=148) were concerned about possible medication side effects. CONCLUSIONS: This analysis shows that SpA represents a considerable burden to patients and society overall in Mexico. It further highlights the need for effective therapies to control peripheral and axial Spondyloarthritis.